Published on 1/30/2018 in the Prospect News Structured Products Daily.
New Issue: RBC prices $166,000 8.7% contingent coupon autocalls tied to two stocks
By Susanna Moon
Chicago, Jan. 30 – Royal Bank of Canada priced $166,000 of autocallable contingent coupon barrier notes due Jan. 15, 2021 linked to the lesser performing of the common stocks of Amgen Inc. and Biogen Inc., according to a 424B2 filing with the Securities and Exchange Commission.
The notes pay a contingent quarterly coupon at an annual rate of 8.7% if each stock closes at or above its 65% coupon barrier on the observation date for that quarter.
The notes will be called at par if each stock closes at or above its initial level on any quarterly observation date after six months.
The payout at maturity will be par unless either stock finishes below its 65% trigger level, in which case investors will be fully exposed to any losses of the worse performing stock.
RBC Capital Markets, LLC is the underwriter.
Issuer: | Royal Bank of Canada
|
Issue: | Autocallable contingent coupon barrier notes
|
Underlying stocks: | Amgen Inc. (Symbol: AMGN) and Biogen Inc. (Symbol: BIIB)
|
Amount: | $166,000
|
Maturity: | Jan. 15, 2021
|
Coupon: | 8.7% annualized, payable quarterly if each stock closes at or above 65% coupon barrier on observation date for that quarter
|
Price: | Par
|
Payout at maturity: | Par unless either stock finishes below 65% trigger, in which case 1% loss per 1% decline of worse performing index
|
Call: | At par if each stock closes at or above initial level on any quarterly observation date beginning June 22, 2018
|
Initial levels: | $185.04 for Amgen, $335.95 for Biogen
|
Trigger levels: | $120,28 for Amgen, $218.37 for Biogen; 65% of initial levels
|
Pricing date: | Jan. 12
|
Settlement date: | Jan. 18
|
Underwriter: | RBC Capital Markets, LLC
|
Fees: | 2.25%
|
Cusip: | 78013XCX4
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.